Mobile Test Unit
Improving Access to Testing
Key Facts
About Lucid Diagnostics
Lucid Diagnostics is a commercial-stage company focused on preventing esophageal adenocarcinoma via early detection of precancerous Barrett's esophagus. Its core achievement is the commercial launch of the EsoGuard/EsoCheck system, a non-endoscopic diagnostic platform with FDA Breakthrough Device designation and established Medicare reimbursement. The company's strategy centers on penetrating the vast, under-screened GERD population through direct sales, strategic partnerships with fire departments, and inclusion in clinical guidelines to drive adoption.
View full company profile